Alkermes Articles
Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid
14 March 2012
Alkermes pulls MAA for Megestrol product
13 March 2012
2011 financial briefs for Alkermes, Allergan, Gilead and Vertex
3 February 2012
FDA finally approves Bydureon
30 January 2012
Alkermes completes Elan DT buy; signs manufacturing deal
19 September 2011
Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS
13 September 2011
US FDA sets PDUFA action dates for Bydureon and peginesatide
12 August 2011
Amylin and Lilly to re-file Bydureon with US FDA sooner than expected with new tQT data
11 July 2011
Alkermes advances pipeline with progress on ALKS 37
18 February 2011
Alkermes shrugs off Bydureon and focuses on pipeline, company reveals in interview with EP Vantage
15 November 2010
Amylin’s diabetes drug Bydureon approval delayed again by US FDA call for more clinical data; 3rd qtr sales data
20 October 2010
US FDA approves Alkermes’ Vivitrol to treat opioid-dependent patients and orphan status for PharmaLink’s Nefecon
13 October 2010
US FDA advisories say no to Arena/Eisai’s obesity drug lorcaserin; back new use for Alkermes’ Vivitrol
17 September 2010
Showing 1-23 of 23 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
